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Objectives: Caspofungin was evaluated as first-line monotherapy of invasive aspergillosis (IA) in
patients with haematological malignancies and undergoing autologous transplants.
Methods: Adults with proven or probable IA, defined strictly according to EORTC-MSG criteria, were
eligible. Those with possible IA were enrolled, but were not evaluable for efficacy unless upgraded to
proven/probable disease within 7 days of registration based on investigations performed within 48 h
after enrolment. Caspofungin dosage was 70 mg (day 1) followed by 50 mg/day. The primary endpoint
was the proportion of patients with complete or partial response at the end of caspofungin therapy in
the modified intention to treat (MITT) group; secondary endpoints were response and survival at day
84 and safety.
Results: In the MITT group (n561), 75% of patients had cancer not in remission (relapsing or refrac-
tory), 85% were neutropenic at enrolment and 49% had a Karnofsky score of 50. At end of treatment,
1 and 19 patients had complete and partial response, respectively [success rate 33% (20/61)], 9 (15%)
achieved stabilization and 31 (51%) had disease progression. One patient was not evaluable. The 6 and
12 week survival rates were 66% (40/61) and 53% (32/60), respectively. Baseline characteristics associ-
ated with survival at day 84 were an underlying disease in remission (not relapsing or refractory) and
Karnofsky score. Recovery from neutropenia at the end of treatment was also significantly associated
with survival. No serious drug-related adverse events or discontinuations due to drug-related adverse
events were observed.
Conclusions: Caspofungin provided an observed response rate compatible with the null hypothesis of
a true response rate of 35%. Underlying disease-related factors had a major impact on results.
Keywords: acute leukaemia, fungal infections, echinocandins
Introduction
Invasive aspergillosis (IA) develops in 5%–10% of patients
treated for acute leukaemia and in up to 40% of recipients of
allogeneic haematopoietic stem cell transplants (HSCTs).1 – 3
Although recent data suggest improved survival,2 in general
IA-associated mortality ranges between 50% and 80% in
patients with leukaemia and up to 70% in HSCT recipients.1 – 7
Confirming a diagnosis of IA before death remains problematic,
particularly because of the difficulty in obtaining cultures and
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biopsies from sterile sites. As a consequence the European
Organization for Research and Treatment of Cancer Infectious
Disease Group and the Mycoses Study Group (EORTC-MSG)
proposed consensus definitions for different levels of diagnostic
certainty.8 These criteria, recently updated,9 take into account
patient risk of developing IA, suggestive clinical presentation,
laboratory data and imaging tests. According to the old criteria,
the diagnosis of probable IA requires microbiological data sup-
porting the likelihood of disease, including a positive culture
and microscopy from a non-sterile site. The new definitions
have added a positive galactomannan (GM) and/or glucan test as
able to support a diagnosis of probability. The two largest ran-
domized clinical trials of IA to date included many patients
based on suggestive radiological imaging, without any micro-
biological confirmation.10,11
Caspofungin has proved effective for salvage therapy of IA
and it has been approved for this indication. Caspofungin is very
well tolerated, even in patients with severe underlying con-
ditions.12 However, there were very little published data about
the efficacy of caspofungin as first-line therapy. For this reason,
we found it important to perform a clinical trial aimed at esti-
mating the efficacy of caspofungin as first-line monotherapy of
patients with proven or probable IA, as defined by strict
EORTC-MSG criteria. Patients with haematological malignan-
cies and autologous HSCT (Group 1) and patients with allo-
geneic HSCT (Group 2) were included in two different strata
and evaluated separately, because response rates (RRs) and sur-
vival differ substantially in these populations. In the present
article we report results among patients with haematological
malignancies or undergoing autologous HSCT. Results from
patients with allogeneic HSCT will be reported separately due to
the very different nature of the patient populations and under-
lying diseases. Data about haematological patients were pre-
sented at the TIMM (Trends in Medical Mycology) Congress in
Torino 2007 as an oral presentation by C. V.
Methods
This was a Phase II, open label, non-comparative, multicentre study
to estimate the efficacy of caspofungin as first-line monotherapy for
IA in patients with haematological malignancies or undergoing
autologous HSCT. Twenty centres in Europe participated in the
study, which was approved by the Protocol Review Committee of
the EORTC (EORTC and EudraCT protocol numbers 65041 and
2004-002944-90, respectively) and by the Ethics Committees of
each participating institution. Written informed consent was required
and enrolment was centralized at the EORTC Data Centre using a
secure web-based system. All case reports were computerized at the
EORTC Data Centre in Brussels, Belgium and reviewed by a Data
Review Committee (DRC) for completeness, accuracy, eligibility
criteria and assessment of the outcome variables. The study was
funded by an unrestricted educational grant by Merck & Co. One
representative from Merck participated in DRC meetings, with no
voting rights. Patients received a 70 mg loading dose of caspofungin
on day 1, followed by 50 mg/day for at least 15 days (or until
failure) and up to 84 days. Dose modifications were made for
patients with body weight .80 kg (70 mg/day), moderate hepatic
failure (70 mg loading dose followed by 35 mg/day) and concomi-
tant administration of liver inducers able to influence caspofungin
concentrations. Addition or modification to protocol therapy in the
absence of efficacy assessment was considered treatment failure.
Evaluations included medical history, physical examination,
Karnofsky score, haematology and chemistry profiles at baseline,
weekly and up to 30 days after treatment. In addition, Aspergillus
GM-ELISA test, blood cultures, sputum cultures, bronchoalveolar
lavage (BAL), aspiration of pulmonary and extrapulmonary lesions,
CSF examination, chest X-rays, sinus or lung CT scans were per-
formed as clinically appropriate. GM tests were performed at least
every 48 h, if possible, especially during the upgrading phase. For
the purpose of this trial a GM test of 0.7 was considered positive,
a value that was the most widely used when the study was con-
ceived. Two positive, consecutive samples in blood or one positive
sample in BAL were needed in order to contribute to a diagnosis of
probable infection.
Study design and entry criteria
The study design is shown in Figure 1. The study included
patients with haematological malignancies in any stage, including
patients with an underlying disease not in remission (relapsing or
refractory) and with probable or proven IA, strictly according to
the EORTC-MSG definitions, with the only exception being that
the GM test was allowed as a confirmation test for probable asper-
gillosis. Patients with possible IA (i.e. those with a halo sign only,
without microbiological confirmation or with host factors and
clinical signs or symptoms compatible with IA but again without
microbiological confirmation) were allowed to start treatment.
However, investigators had 7 days to upgrade the case to proven
or probable IA based on culture or serological tests performed
prior to or within 48 h after registration, but with results pending.
Patients not upgraded were discontinued from the study; these
patients were assessed for safety but not for efficacy. Other entry
criteria included age 18 years and not having received either an
investigational agent within 14 days prior to registration or an
empirical antifungal therapy (not including an echinocandin) for
.72 h before inclusion. Oral prophylaxis had to be discontinued
at study entry. No intravenous prophylaxis was allowed, unless
with fluconazole. A history of allergy to echinocandins, severe
renal failure, significant liver function test abnormalities, severe
hepatic insufficiency, inadequately treated bacterial infection, docu-
mented HIV infection, status of pregnancy or lactation, conditions
hampering compliance and a Karnofsky score of 20 were exclu-
sion criteria.
Response assessment criteria
The study was evaluated using standard response assessment cri-
teria.9 Briefly, every case was assessed by clinical and radiological
criteria as having achieved complete or partial response (success),
stabilization or disease progression (failure). The reduction in the
sum of the area and longest diameter of all measurable lesions
attributable to IA from baseline to end of therapy (EOT) was calcu-
lated as follows: [sum of the area (or longest diameter) at baseline–
sum of the area (or longest diameter) at EOT]/sum of the area (or
longest diameter) at baseline.
A negative reduction indicated an increase in the lesion area or
longest diameter. At least a 50% reduction in the size of the lesion
was required to qualify the case as partial response, while a
reduction of ,50% qualified the patient as having stable disease.
The modified intention to treat (MITT) group included all patients
with confirmed probable/proven IA who received at least one dose
of caspofungin treatment.
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Study endpoints and statistical planning
The primary endpoint was the proportion of MITT patients with
complete or partial response to treatment at EOT. The secondary
endpoints were response to treatment and survival at day 84 after
enrolment, and safety, as defined by the proportion of drug-related
adverse events, serious drug-related adverse events and drug-related
adverse events leading to treatment discontinuation. The study was
planned according to a one-stage Fleming design. Based on RRs
observed in a previous study,9 52 eligible and evaluable patients
were needed, in order to show that the true RR was .35% (with a
power of 95% in the case of a true RR of 55%), using a one-sided
significance level of 10%. To reject the null hypothesis of a true RR
of 35% (and therefore to recommend the tested regimen for
further studies), 23 complete or partial responses out of 52 eligible
patients were required (observed RR 44%). A non-eligibility rate of
10% and a non-upgrading rate of 30% were forecast; thus, the final
sample size estimation was planned to include at least 87 patients.
Fisher’s exact test was used to test the statistical significance of
differences in discrete data and the Mann–Whitney U-test to
compare continuous variables such as Karnofsky score. P,0.05
was considered statistically significant. As most of the deaths
attributable to IA occur by day 84, the binary survival status at day
84 was considered as an endpoint. A logistic regression model was
constructed to determine baseline characteristics independently
related to survival at day 84. The model took into account the gra-
nulocyte count at EOT, as well, with the consequence that the result-
ing logistic regression model cannot be used to predict survival
status at start of treatment. Gender, Karnofsky score, status of under-
lying disease, diagnosis of IA, site of infection, prior antifungal
therapy, being neutropenic at enrolment and EOT, and having been
neutropenic for .10 days during the 60 days prior to enrolment
were variables included in the analysis. The logistic regression
model was obtained using stepwise forward selection of variables.
Results
In total, 129 patients were enrolled between 26 April 2005 and
31 March 2007. Sixty-eight patients were ineligible due to lack
of microbiological criteria (n¼64) or absence of major or minor
clinical criteria (n¼4). The remaining 61 cases were evaluable
for the MITT analysis, resulting in a statistical power of 0.97. In
this study, 88 patients were initially registered as having possible
aspergillosis. Of these, 24 (27%) were upgraded to proven or
probable IA.
Baseline characteristics and demographics
As shown in Table 1, all patients had a haematological malig-
nancy treated with chemotherapy or autologous HSCT and were
affected by proven or probable IA. Neutropenia (,500 cells/mm3)
at enrolment and/or for .10 days within the 60 days before was
present in more than two-thirds of the patients. At EOT, the rate
Haematological malignancies
or autologous HSCT
Signs, symptoms and/or
laboratory/radiological data 
suggestive of 
probable/proven/possible IA
Proven/probable Possible
Registration/start study treatment
YesContinue study 
treatment
End of study treatment
(min 14 days – max 84 days)
SUCCESS FAILURE
Shifting to oral drugs 
allowed for maintenance 
or secondary prophylaxis
Further treatment at 
the discretion of the 
investigator
No
Upgraded to probable/proven IA within 7 days from 
registration, based on tests performed prior to or within 48 h
after registration
Stop study treatment 
(evaluable for safety)
Figure 1. Study design.
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of neutropenia was 33% (19/58) (data not shown in the table;
missing for three patients). The majority of the patients had a
haematological underlying disease that was not in remission
(relapsing or refractory) and the median Karnofsky score at
enrolment was 60, with 49% (30/61) of the patients with a score
of 50. About two-thirds of the patients (41 of 61; 67%) had
received antifungal prophylaxis until enrolment. Regimens used
included oral or intravenous fluconazole in 33 cases, oral itraco-
nazole in 5 cases and another oral combination in the other
cases. Empirical antifungal therapy was administered in 16 of
61 (26%) patients, of whom 8 had also received antifungal pro-
phylaxis. Regimens used for empirical therapy included ampho-
tericin B (usually the standard formulation) in nine cases and
voriconazole in seven cases. Empirical antifungal therapy was
administered for 1, 2 and 3 days in three, three and nine patients,
respectively. One patient received empirical deoxycholate
amphotericin B for 7 days and was kept in the study because
this was considered as a minor violation by the DRC. Criteria
supporting a diagnosis of probable IA were mainly a positive
GM test, with or without positive culture or cytological examin-
ation. The median GM value in patients with positive test results
was 1.45 (0.7–6.33) in blood and 3.57 (0.7–23.5) in BAL. A
total of 16 of 61 patients had positive cultures for Aspergillus.
Pathogens isolated were Aspergillus fumigatus (n¼15),
Aspergillus flavus (n¼2) and Aspergillus niger (n¼1). Two
patients had two different species isolated. The most common
clinical signs and symptoms were sputum production (92%), fever
(77%), cough (67%), dyspnoea (51%) and chest pain (38%).
Outcomes
The mean duration of treatment was 27 days (SD +24), with a
median duration of 15 days (range 3–84). RRs at EOT are
shown in Table 2. Among the nine patients with stable disease
at EOT, six survived day 84. Of them, two did not receive any
additional antifungal treatment after 3 weeks of caspofungin
Table 1. Baseline patient characteristics in the MITT group
Characteristic MITT (N¼61)
Age in years, median (range) 64 (19–86)
Gender, n (%)
male 43 (70)
Prior antifungal therapy, n (%)
none 12 (20)
empirical 8 (13)
prophylactic 33 (54)
empirical and prophylactic 8 (13)
Underlying disease not in remission (relapsing or refractory), n (%) (not assessable for two patients) 44 (75)
Underlying conditions, n (%)
ALL 4 (7)
AML 34 (56)
chronic leukaemia 9 (15)
lymphoma (NHL/HD) 11 (18)
other (MDS, multiple myeloma) 3 (5)
Diagnosis of IA, n (%)
proven 1 (2)
probable 60 (98)
Site of infection, n (%)
lower respiratory tract 60 (98)
sino-nasal infection 1 (2)
Neutropenia (,500 cells/mm3) at start of study treatment, n (%) (not assessable in one case) 51 (85)
Neutropenia (,500 cells/mm3) for .10 days in the previous 60 days, n (%) 44 (72)
Criteria supporting the diagnosis of probable IA, na
positive GM antigen 44
positive culture for Aspergillus 8
positive GM antigen and culture 5
positive GM antigen, culture and cytological examination 1
positive cytological examination 1
positive cytological examination and culture 1
ALL, acute lymphocytic leukaemia; AML, acute myeloid leukaemia; NHL/HD, non-Hodgkin’s lymphoma/Hodgkin’s disease; MDS,
myelodysplastic syndrome.
aOut of 60 patients with probable IA.
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and four received maintenance therapy with an oral azole (two
itraconazole and two voriconazole). Response to treatment by
baseline patient characteristics is shown in Table 3. The
Karnofsky score at the start of treatment had a statistically sig-
nificant impact on the outcome (Mann–Whitney U-test;
P¼0.04). Although not statistically significant, more treatment
failures were observed among patients with acute versus chronic
leukaemia, with neutropenia at the start of study treatment and,
especially, among those with a history of severe and prolonged
neutropenia in the 60 days prior to enrolment (P¼0.07).
Survival data at day 84 are reported for 60 patients, with 1
patient lost to follow-up. The survival rates at 6 and 12 weeks
were 66% (40/61) and 53% (32/60), respectively. The most
Table 2. Response to treatment at EOT in the MITT population
Response
MITT population (N¼61)
n % (95% CI)
Complete 1 2 (0–9)
Partial 19 31 (20–44)
Stable disease 9 15 (7–26)
Disease progression 31 51 (38–64)
Not evaluablea 1 2 (0–9)
aPatient refused treatment.
Table 3. Response to treatment at EOT by baseline characteristics
Success, n/N (%) P value
Gender
male 15/43 (35) 0.77
female 5/18 (28)
Underlying condition
acute leukaemia 10/38 (26) 0.22
chronic leukaemia 5/9 (56)
other 5/14 (36)
Status of underlying disease (not assessable for two patients)
not in remission (relapsing or refractory) 15/44 (34) 0.75
in remission 4/15 (27)
Diagnosis of aspergillosis
proven at start of treatment 0/1 (0) 1
probable at start of treatment 12/36 (33)
possible at start of treatment, upgraded to probable 8/24 (33)
GM value (GM was not evaluated in one patient)a
not positive 3/9 (33) 1
positive 17/51 (33)
Prior antifungal therapy
no 6/12 (50) 0.26
empirical (only or in combination with prophylaxis) 5/16 (31)
prophylaxis 9/33 (27)
Previous bacterial infection
no 15/47 (32) 1
yes 5/14 (36)
Site of infection
lower respiratory tract 19/60 (32) 0.33
sino-nasal 1/1 (100)
Neutropenia for .10 days in the previous 60 days
no 9/17 (53) 0.07
yes 11/44 (25)
Neutropenia at enrolment (not assessable in one case)
no 5/9 (56) 0.14
yes 15/51 (29)
Karnofsky score
,50 2/14 (14) 0.04
50–60 7/21 (33)
.60 11/26 (42)
aGM was positive in the proven IA case.
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common 12 week cause of death was IA, alone (n¼18) or in
association with other causes, such as haemorrhage (two cases),
the underlying malignancy (five cases), a non-fungal concomi-
tant infection (one case) and other causes (two cases). Variables
significantly associated with survival at day 84 in the multi-
variate analysis were having an underlying disease in remission
(not relapsing or refractory) at baseline (remission versus not in
remission: OR 37.52; 95% CI 2.64 to .999), Karnofsky score at
start of treatment (for each increase in the score the odds of sur-
vival increased by 88%, i.e. OR 1.88; 95% CI 1.12–3.58) and
presence of neutropenia at EOT (presence versus absence: OR
0.04; 95% CI ,0.001–0.38). RRs of 16% (3/19) and 41%
(16/39) were observed among patients who were and were not
neutropenic at EOT, respectively (P¼0.08). Neutropenia at EOT
was not assessable in three patients. Among the nine patients
who were not neutropenic at the start of therapy, one was lost to
follow-up. Five of the other eight (63%) survived to day 84.
Antifungal prophylaxis and/or empirical therapy had no influ-
ence on response to treatment and survival, nor did the dose per
weight of caspofungin administered.
Radiological assessments
Radiological assessments were available in 49 of 61 (80%)
patients. Of the 12 patients with no radiological assessments at
EOT, 11 had a clinical assessment of disease progression and
one voluntarily refused treatment and was not assessed. In four
patients, the radiological assessment was based on chest X-ray
data only. Therefore, exact calculations of the change in size of
the lesion were performed in 45 patients. Partial response was
associated with a 73% (53%–90%) median decrease in the sum
of the areas of all measurable lesions attributable to IA. A
median 36% reduction was noted for patients with stable
disease. Conversely, patients with disease progression differed
significantly, with a median increase in the lesion size of 103%
(95% CI 69–421). No differences were demonstrated in terms
of defervescence, sputum production, cough, dyspnoea and chest
pain between responding and stabilized patients.
Safety
Of the 129 patients included in the safety analysis, 15% (n¼19)
had drug-related adverse events. There were no serious
drug-related adverse events or drug-related adverse events
leading to caspofungin discontinuation. Grade III or IV adverse
events categorized as ‘likely related’ by the local investigator
were all laboratory abnormalities in g-glutamyl transferase
(n¼5), alkaline phosphatase (n¼4), bilirubin (n¼2), aspartate
aminotransferase (n¼1) and kalaemia (n¼3). No grade V
adverse events were noted as ‘likely related’ by the local
investigator.
Discussion
In our study 33% (95% CI 21–46) of patients in the MITT
analysis had a favourable response (complete and partial) at the
end of caspofungin therapy. The role of the severity of the
underlying disease was quite evident in this study. First, patients
with acute leukaemia, Karnofsky score ,50 and neutropenia at
the start of study treatment appeared less likely to have a
favourable response. Secondly, the status of the underlying
disease at baseline, the Karnofsky score and being neutropenic
at EOT were all significantly associated with survival at day 84.
These results suggest that in patients with persistent neutropenia
and an underlying disease not in remission (relapsing or refrac-
tory), treatment of proven/probable IA presents a unique chal-
lenge. Response to treatment and survival were actually lower
among patients with ‘uncontrolled cancer (active malignancy)’
than in other patients in the Ambiload study, as well.11 The
status of the underlying disease was also found to be one of the
factors significantly associated with survival in a recent French
study.13
In terms of diagnostic certainty, this is the first trial to apply
the EORTC-MSG criteria strictly.8 We enrolled only patients
with microbiological data supporting a diagnosis of proven/prob-
able aspergillosis and excluded cases of possible disease (i.e.
patients with halo sign only). This is important because better
outcomes have been observed in patients enrolled solely on the
basis of radiological signs than in patients with proven or prob-
able disease.14 Indeed, patients enrolled based on the presence
of the halo sign only had better RRs than other patients in both
the Phase II and III voriconazole studies and in the Ambiload
study,10,11,15 suggesting that at least some of the patients with
radiological signs only actually do not have IA. It is important
to note that requiring some microbiological confirmation of IA
does not mean treating patients at a more advanced stage of
disease, since treatment was always started at first clinical signs
and empirical therapy was allowed, although for no longer than
72 h. Multivariable analyses showed that previous antifungal
therapy or prophylaxis had no impact on response to treatment
and survival.
Debate exists as to whether or not patients with stable disease
should be considered as success of therapy. In our study, the
main difference between stable disease and partial response was
in the extent of decrease in the size of the lesions, with no
difference in clinical outcomes, including GM values. As
suggested in a recent position paper, given the severity of both
the underlying condition and the complicating infection, there
may be cases in which both physicians and patients might con-
sider stable disease as an acceptable outcome.16
This study was a non-comparative Phase II study designed to
explore the efficacy of caspofungin as first-line therapy of IA.
When the present study was designed, the only available model
for setting reference RRs and calculating the sample size was the
voriconazole versus amphotericin B study.10 However, this
choice, although forced, might have been inappropriate, because
of the existence of important methodological differences between
this study and the one we were planning. Indeed, the voriconazole
study evaluated response to treatment at day 84, regardless of any
therapeutic modification, and not at EOT, as in our study; it
included both patients with haematological malignancies and allo-
geneic transplants and allowed the inclusion of patients lacking
any microbiological or serological documentation of IA.
In conclusion, caspofungin achieved an EOT RR of 33% in
the MITT population and a day 84 survival rate of 53%. We
found that an underlying disease not in remission (relapsing or
refractory), a Karnofsky score of ,50 and persistent neutrope-
nia were all negatively associated with survival. While the
planned null hypothesis of a true RR of 35% could not be
rejected, it is possible that this was related to the very high-
risk patient population included and to the choice of enrolling
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only patients with a high degree of disease certainty (proven/
probable IA). Comparisons between trials are often impossible,
because of the differences in definitions and patient popu-
lations and should, therefore, be interpreted with great caution.
In this study, RRs at EOT and survival appeared to be slightly
lower than those obtained with voriconazole and liposomal
amphotericin B in patients with a similar disease certainty
(with much better safety), but comparable to those obtained
with the same drugs in patients with a similar underlying
disease status. We do not know what the RR was in the vori-
conazole and liposomal amphotericin B trials among patients
who had at the same time a true proven/probable disease and
an advanced haematological neoplasm.
Acknowledgements
Data about haematological patients were presented at the TIMM
(Trends in Medical Mycology) Congress in Torino 2007 as an
oral presentation by C. V.
Participants: H. Akan, Ankara University School Of
Medicine—Cebeci Campus, Ankara, Turkey; M. Aoun, Institut
Jules Bordet, Brussels, Belgium; A. Botelho De Sousa, Hospital
Dos Capuchos–Centro Hospitalar De Lisboa, Lisbon, Portugal;
O. Cornely, Universitaetskliniken Ko¨ln, Cologne, Germany;
P. Donnelly, Radboud University Nijmegen Medical Center,
Nijmegen, The Netherlands; C. Doyen, Cliniques Universitaires
De Mont Godinne, Yvoir, Belgium; P. Frere, CHU Sart-Tilman,
Liege, Belgium; A. Gallamini, Ospedale Santa Croce, Cuneo,
Italy; A. Giagounidis, St Johannes Hospital – Mediz. Klinik II,
Duisburg, Germany; W. Heinz, Medizinische Poliklinik Der
Universitaet Wu¨rzburg, Wu¨rzburg, Germany; R. Herbrecht,
Hopital Universitaire Hautepierre, Strasbourg, France;
C. C. Kibbler, Royal Free Hospital, London, UK; V. Korten,
Marmara University Hospital, Istanbul, Turkey; J. Maertens, UZ
Gasthuisberg, Leuven, Belgium; R. Martino, Hospital De La
Santa Creu I Sant Pau, Barcelona, Spain; L. Pagano, Policlinico
Universitario A. Gemelli–Universita` del Sacro Cuore, Rome,
Italy; M. Ruhnke, Charite-Universitaetsmedizin Berlin—Campus
Mitte, Berlin, Germany; D. Selleslag, AZ St Jan, Brugge,
Belgium; A. Thiebaut, CHU Lyon-Hopital Edouard Herriot,
Lyon, France; E. Thiel, Charite-Universitaetsmedizin Berlin—
Campus Benjamin Franklin, Berlin, Germany; and A. J. Ullmann,
Johannes Gutenberg Universitaetskliniken, Mainz, Germany.
Funding
The study was funded by an unrestricted educational grant by
Merck & Co. Writing assistance was funded by Merck & Co.
Transparency declarations
C. V. has been a consultant to Astellas, Gilead, MSD, Pfizer and
Schering-Plough, has been a member of speakers’ bureaus for
Gilead, Pfizer and Schering-Plough, and has received research
grants from Pfizer, Merck, Gilead, BMS and Abbott. R. H. has
been a consultant to Astellas, Gilead, MSD, Pfizer and
Schering-Plough, has been a member of speakers’ bureaus for
Gilead, Pfizer and Schering-Plough, and has received research
grants from Pfizer. O. M. has received research grants from
Bio-Rad, Essex/Schering-Plough, Merck, Pfizer, Roche
Diagnostics and Wako, and has been a consultant for and has been
a speaker at conferences organized by Essex/Schering-Plough,
Merck and Pfizer. M. S. is an employee of Merck & Co., Inc.,
USA and owns stock and/or stock options in the company. A. U.
has been a consultant to Astellas, Basilea, Gilead, MSD,
Schering-Plough and Pfizer, and has been a member of speakers’
bureaus for Astellas, Gilead, MSD, Schering-Plough and
Pfizer. R. M. has been a speaker for Merck/MSD and Zeneus/
Cephalon. J. M. has received research grants from Merck/MSD
and Pfizer, is a consultant to Astellas, Bio-Rad, Merck/MSD,
Nektar, Pfizer, Schering-Plough, F2G, Zeneus/Cephalon and
Luminex, and has served on the speakers’ bureaus of Astellas,
Bio-Rad, Merck/MSD, Pfizer, Schering-Plough, Zeneus/Cephalon
and Viropharma. All other authors: none to declare.
The study design was discussed with Merck representatives
and finally approved by the EORTC Protocol Review Committee.
A Merck representative was present at every meeting of the DRC
without voting rights. Results were discussed with Merck repre-
sentatives, who played no role in the study analysis.
Writing assistance was provided by Wendy Horn PhD.
Author contributions
C. V. designed the study and wrote the study protocol and the
final article. R. H., H. A., O. M. and A. J. U. included patients
and were members of the DRC. L. B. is the EORTC Clinical
Research Physician responsible for the EORTC Infectious
Disease Group and was part of the DRC. A. S., A. Gallamini
and A. Giagounidis were the main contributors in terms of
patients. L. M. is the EORTC Infectious Disease Group Data
Manager. R. M. provided cases and was the trial co-coordinator.
M. P. and L. A. are the Group Statisticians. M. S. is the Merck
representative, who participated in the DRC meetings with no
voting rights. J. M. included cases and was the EORTC
Infectious Disease Chairman at the time the study was conducted.
References
1. Pagano L, Caira M, Candoni A et al. The epidemiology of fungal
infections in patients with haematologic malignancies: the
SEIFEM-2004 study. Haematologica 2006; 91: 1068–75.
2. Cordonnier C, Ribaud P, Herbrecht R et al. Prognostic factors for
death due to invasive aspergillosis after haematopoietic stem cell trans-
plantation: a 1-year retrospective study of consecutive patients at
French transplantation centres. Clin Infect Dis 2006; 42: 955–63.
3. Upton A, Kirby DA, Carpenter P et al. Invasive aspergillosis
following haematopoietic cell transplantation: outcomes and prognostic
factors associated with mortality. Clin Infect Dis 2007; 44: 531–40.
4. Lin S, Schranz J, Teutsch SM. Aspergillosis case-fatality rate:
systematic review of the literature. Clin Infect Dis 2001; 32: 358–66.
5. Ribaud P, Chastang C, Latge JP et al. Survival and prognostic
factors of invasive aspergillosis after allogeneic bone marrow trans-
plantation. Clin Infect Dis 1999; 28: 322–30.
6. Wald A, Leisenring W, van Burik JA et al. Epidemiology of
Aspergillus infections in a large cohort of patients undergoing bone
marrow transplantation. J Infect Dis 1997; 175: 1459–66.
7. Pagano L, Caira M, Nosari A et al. Fungal infections in recipients
of hematopoietic stem cell transplants: results of the SEIFEM B-2004
study - Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie
Maligne. Clin Infect Dis 2007; 45: 1161–70.
Viscoli et al.
1280
8. Ascioglu S, Rex JH, de Pau B et al. Defining opportunistic inva-
sive fungal infections in immunocompromised patients with cancer and
haematopoietic stem cell transplants: an international consensus. Clin
Infect Dis 2002; 34: 7–14.
9. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of
invasive fungal disease from the European Organization for Research
and Treatment of Cancer/Invasive Fungal Infections Cooperative
Group and the National Institute of Allergy and Infectious Diseases
Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect
Dis 2008; 46: 1813–21.
10. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole
versus amphotericin B for primary therapy of invasive aspergillosis. N
Engl J Med 2002; 347: 408–15.
11. Cornely O, Maertens J, Bresnkik M et al. Liposomal amphoteri-
cin B as initial therapy for invasive mold infection: a randomized trial
comparing a high-loading dose regimen with standard dosing
(AmBiLoad trial). Clin Infect Dis 2007; 44: 1289–97.
12. Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of cas-
pofungin for treatment of invasive aspergillosis in patients refractory to
or intolerant of conventional antifungal therapy. Clin Infect Dis 2004;
39: 1563–71.
13. Nivoix Y, Velten M, Letscher-Bru V et al. Factors associated with
overall and attributable mortality in invasive aspergillosis. Clin Infect
Dis 2008; 47: 1176–84.
14. Greene RE, Schlamm HT, Oestmann JW et al. Imaging findings
in acute invasive pulmonary aspergillosis: clinical significance of the
halo sign. Clin Infect Dis 2007; 44: 373–9.
15. Denning DW, Ribaud P, Milpied N et al. Efficacy and safety of
voriconazole in the treatment of acute invasive aspergillosis. Clin Infect
Dis 2002; 34: 563–71.
16. Segal B, Herbrecht R, Stevens DA et al. Defining responses to
therapy and study outcomes in clinical trials of invasive fungal dis-
eases: Mycoses Study Group and European Organization for
Research and Treatment of Cancer consensus criteria. Clin Infect Dis
2008; 47: 674–83.
Caspofungin: first-line therapy in invasive aspergillosis
1281
